Shearman, Wilson Sonsini on WuXi Biologics’ $511 mln HK trading debut
BY John Kang, Reuters |
Wilson Sonsini Goodrich & Rosati and Shanghai-headquartered Fangda Partners have advised WuXi Biologics, a Chinese contract drug research and development company, on its $511 million IPO in Hong Kong.